ReviewTherapeutics and clinical risk management2022

Practical Management for Use of Eculizumab in the Treatment of Severe, Refractory, Non-Thymomatous, AChR + Generalized Myasthenia Gravis: A Systematic Review.

Waqar Waheed et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.